A phase I dose escalation study to assess the maximum tolerated dose and feasibility of combining oral capecitabine (Xeloda) and conformal radiotherapy (CRT) for patients with unresectable hepatocellular carcinoma, multiple hepatic metastases or cholangiocarcinoma.
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2017
At a glance
- Drugs Capecitabine (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Adverse reactions
- 16 Nov 2007 Status changed from recruiting to discontinued (lack of accrual).
- 18 Nov 2005 New trial record.